AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01020708
Drug: ALTH12-1:4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
Trial: NCT01020708
Drug: ALTH12-2:4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
Trial: NCT01051206
Drug: 6% hydroxyethyl Stach 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
Trial: NCT00334282
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo (800 mg tablet) once daily
Trial: NCT03759964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of IV isotonic serum saline at day 1 following surgery
Trial: NCT01281228
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion
Trial: NCT04049110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
Trial: NCT00162266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Trial: NCT00764907
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV during reinduction
Trial: NCT00764907
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV during reinduction
Trial: NCT00764907
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV during reinduction
Trial: NCT00764907
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally during reinduction
Trial: NCT00764907
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally during reinduction
Trial: NCT02270827
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous medication
Trial: NCT00620438
Drug: Lumefantrine-artemether and rifampicin
RxNorm normalized name: artemether and lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
Trial: NCT01821456
Drug: Antiinfectives
RxNorm normalized name: Antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To analyze to efficacy of (novel) drug therapies
Trial: NCT00012558
Drug: inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04336891
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
Trial: NCT04336891
Drug: Estradiol ovules
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
Trial: NCT04336891
Drug: Testosterone gel + Estradiol ovules
RxNorm normalized name: estradiol / testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
Trial: NCT01749579
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
Trial: NCT00161993
Drug: Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01400516
Drug: calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg of calcium citrate
Trial: NCT02865915
Drug: MLE4901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
Trial: NCT02865915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match active drug
Trial: NCT00357656
Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
RxNorm normalized name: factor VIII Injection [Recombinate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h.
Trial: NCT00357656
Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
RxNorm normalized name: factor VIII Injection [Recombinate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
Trial: NCT00918021
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00615056
Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Trial: NCT00615056
Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Trial: NCT00615056
Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Trial: NCT00615056
Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Trial: NCT03226340
Drug: S-amlodipine 2.5mg + Chlorthalidone 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
Trial: NCT02776033
Drug: GSK2982772
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Trial: NCT03733171
Drug: diluted epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
Trial: NCT00134212
Drug: Dopexamine and norepinephrine
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00134212
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02776033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Trial: NCT02603809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
Trial: NCT03662984
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare ciprofibrate
Trial: NCT02675335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02759224
Drug: Lafutidine
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04031833
Drug: MAT2203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encochleated amphotericin B
Trial: NCT01145768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01268111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01702740
Drug: 1 mg/kg CNTO 136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Trial: NCT01702740
Drug: 4 mg/kg CNTO 136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Trial: NCT01702740
Drug: 10 mg/kg CNTO 136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Trial: NCT01702740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Trial: NCT02419170
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01504321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated lactose powder
Trial: NCT00853840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
Trial: NCT02515942
Drug: CLG561
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02515942
Drug: LFG316
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02310919
Drug: Low dose hCG plus FSH co-trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
Trial: NCT02310919
Drug: Standard dose of hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of hCG (10,000 or 5,000 IU) trigger
Trial: NCT03099148
Drug: LY3337641 (T1)
RxNorm normalized name: FORTISCARE T1 (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PO
Trial: NCT03099148
Drug: LY3337641 (T2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PO
Trial: NCT02365285
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule prior to the infusion of intralipid/heparin
Trial: NCT02365285
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
Trial: NCT00821249
Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Trial: NCT04348045
Drug: ARM C FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
Trial: NCT02144155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo drug
Trial: NCT02995044
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
Trial: NCT02995044
Drug: SPF Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT00233623
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00233623
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03127657
Drug: Cock's comb extract 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically twice daily for 12 weeks
Trial: NCT04398758
Drug: SanaCutan Basiscreme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
Trial: NCT03222843
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03606681
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
Trial: NCT03606681
Drug: TheraCal LC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
Trial: NCT01727141
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
Trial: NCT01727141
Drug: QAB149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Trial: NCT01727141
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Trial: NCT01727141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Trial: NCT00448071
Drug: MTR107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03336216
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: specified dose on specified days
Trial: NCT03336216
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT01129843
Drug: Directly observed home based daily iron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
Trial: NCT03488316
Drug: Manipulation of the temporary filling material based on Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
Trial: NCT02477501
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous infusion
Trial: NCT03240133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral liquid formulation to match BCX7353
Trial: NCT02262481
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01321788
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
Trial: NCT01636713
Drug: GSK573719/VI 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Trial: NCT01636713
Drug: GSK573719/VI 125/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Trial: NCT01636713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via Novel Dry Powder Inhaler Once a day
Trial: NCT00666757
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-80 mgs orally daily for 12 weeks
Trial: NCT02170766
Drug: BIBR 1048 medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02597556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
Trial: NCT02273570
Drug: standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
Trial: NCT02273570
Drug: Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
Trial: NCT00094406
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01231581
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
Trial: NCT01231581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
Trial: NCT02646852
Drug: PLX038
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01879228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Trial: NCT00473525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD
Trial: NCT00473525
Drug: PF-00734200 10 mg QD
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg QD
Trial: NCT01313819
Drug: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
Trial: NCT03335254
Drug: TSX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.